Chidamide plus chemotherapy for new nodal TFH cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies whether adding chidamide to a combination chemotherapy plan (azacitidine, liposomal mitoxantrone, and prednisone) works better for people newly diagnosed with nodal T-follicular helper (TFH) cell lymphoma. It’s testing a treatment strategy after diagnosis to improve disease control and outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis from a biopsy of nodal T-follicular helper (TFH) cell lymphoma
- You are older than 18 years
- You must have sufficient blood counts and organ function (neutrophils, platelets, liver tests, and kidney function)
- Your heart pumping strength must be adequate (measured by echocardiogram, LVEF ≥50%)
- You should be able to do daily activities with limited help (ECOG 0–2) and expect to live more than 3 months
- You have not had any prior chemotherapy, radiation, or other cancer treatment for this lymphoma
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug combination (called CAPCT) for people with a type of lymphoma called peripheral T-cell lymphoma. It might be an option for those who can't have standard chemotherapy, and the goal is to see if it can help control the disease.
This trial is testing a combination of two targeted drugs – chidamide (an HDAC inhibitor) and golidocitinib (a JAK inhibitor) – for people with peripheral T-cell lymphoma that has come back or hasn't responded to prior treatments. The goal is to see if this combination can shrink tumors or stop the cancer from growing.
This trial tests a combination of two targeted drugs, Chidamide and Duvalisib, for people with peripheral T-cell lymphoma or NK/T-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this drug combination can help shrink or control the lymphoma.
This Phase 3 study compares two chemo options—CHOP alone versus CHOP plus AC—for people whose peripheral T-cell lymphoma is the “T-follicular helper” type (PTCL-TFH). The goal is to see which treatment works better for people who have not received lymphoma treatment yet.
This trial tests a combination of three drugs (chidamide, decitabine, and an immunotherapy) for people with classical Hodgkin lymphoma that has come back or not responded to at least two prior treatments. It is for patients who cannot or choose not to have a stem cell transplant.
This trial tests a combination of two oral targeted drugs (chidamide and decitabine) plus an immunotherapy drug (anti-PD-1 antibody) for people with classical Hodgkin lymphoma that has not responded to at least two prior treatments and who cannot or choose not to have a stem cell transplant. The goal is to see if this three-drug combination can shrink tumors and help control the disease.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.